Toward optimal therapy for inhibitors in hemophilia

Blood

Volumn 124, Issue 23, 2014, Pages 3365-3372

  Kempton, Christine L ^a,b   Meeks, Shannon L ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ALLOANTIBODY; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FACTOR VIII SQ; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; GENE THERAPY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MORBIDITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT CARE; PATIENT RISK; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HEMORRHAGE; IMMUNOLOGY; PROCEDURES; TRENDS;

CHEMOPREVENTION; FACTOR VIIA; FACTOR VIII; GENETIC THERAPY; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; RECOMBINANT PROTEINS;

EID: 84913580230     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-577643     Document Type: Review

References (60)

1. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954-1962.
2. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007;138(3):305-315.
3. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia. 2012;18(2):268-275.
4. Lindvall K, von Mackensen S, Elmstahl S, et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer. 2014;61(4):706-711.
5. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2(6):899-909.
6. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8(2):83-90.
7. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
8. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121(11):1944-1950.
9. Young G, Ebbesen LS, Viuff D, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008;19(4):276-282.
10. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010;116(25):5734-5737.
11. Chitlur M, Rivard GE, Lillicrap D, Mann K, Shima M, Young G. Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(1):103-106.
12. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004;10(4):347-351.
13. Tran HT, Sorensen B, Rea CJ, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia. 2014;20(3):369-375.
14. Kruse-Jarres RSt., Louis J, Greist A, et al. Recombinant porcine sequence factor VIII (OBI-1): Results from a prospective clinical study investigating the treatment of serious bleeds in patients with acquired hemophilia A. Haemophilia. 2014;20(suppl 3):1.
15. Hay CR, Lozier JN, Lee CA, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost. 1996;75(1):25-29.
16. Livnat T, Martinowitz U, Azar-Avivi S, et al. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study. Haemophilia. 2013;19(5):782-789.
17. Doshi BS, Gangadharan B, Doering CB, Meeks SL. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PLoS One. 2012;7(10):e48172.
18. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost. 2009;7(4):658-664.
19. Oldenburg J, Albert T. Novel products for haemostasis-current status. Haemophilia. 2014; 20(suppl 4):23-28.
20. Ivanciu L, Toso R, Margaritis P, et al. A zymogenlike factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol. 2011;29(11):1028-1033.
21. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206-213.
22. Dockal M, Hartmann R, Fries M, et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem. 2014;289(3):1732-1741.
23. Waters EK, Genga RM, Thomson HA, et al. Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013;11(6):1137-1145.
24. Leissinger C, Gringeri A, Antmen B, et al. Antiinhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011; 365(18):1684-1692.
25. Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013;19(5):736-743.
26. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904-1913.
27. Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;14(3):466-475.
28. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13(suppl 1):1-22.
29. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost. 2009;7(9): 1446-1456.
30. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9(4):436-463.
31. Nakar CT, Manco-Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):575.
32. Coppola A, Margaglione M, Santagostino E, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost. 2009;7(11): 1809-1815.
33. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87(1):52-57.
34. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica. 2001;86(11):1186-1193.
35. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J. Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans? Haemophilia. 2011;17(3): 483-489.
36. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6):1335-1344.
37. Meeks SL, Chapman RL, Kempton C, Dunn AL. Late immune tolerance induction in haemophilia A patients. Haemophilia. 2013;19(3):445-448.
38. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang. 1999;77(suppl 1):33-37.
39. Kreuz W, Ettingshausen CE, Auerswald G, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica. 2003;88(6):EREP04.
40. van Velzen AS, Peters M, van der Bom JG, Fijnvandraat K. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br J Haematol. 2014;16(4):485-95.
41. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia. 2007;13(suppl 5):73-77.
42. Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013;121(11): 2108-2116.
43. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood. 2008;112(8):3303-3311.
44. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160(2):153-170.
45. Franchini M, Mannucci PM. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br J Haematol. 2014;165(5):600-608.
46. Leissinger C, Josephson CD, Granger S, et al. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014;112(3):445-458.
47. Barnes C, Brown SA, Curtin J, Dunkley S. When is enough ... enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors. Haemophilia. 2014;20(4):e275-e279.
48. DiMichele D, Kroner B. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. Haematologica. 2000;85(10 suppl): 40-42; discussion 42-44.
49. Antun A, Monahan P, Manco-Johnson M, et al. Natural history of inhibitor recurrence following successful immune tolerance induction [abstract]. Blood (ASH Annual Meeting Abstracts). 2013; 122(21):1106.
50. Kempton CL, Allen G, Hord J, et al. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012; 87(9):933-936.
51. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998;79(4): 762-766.
52. Puetz J, Soucie JM, Kempton CL, Monahan PE. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia. 2014;20(1):25-31.
53. Batorova A, Morongova A, Tagariello G, Jankovicova D, Prigancova T, Horakova J. Challenges in the management of hemophilia B with inhibitor. Semin Thromb Hemost. 2013;39(7): 767-771.
54. Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia. 2003; 9(3):269-271.
55. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
56. Markusic DM, Hoffman BE, Perrin GQ, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med. 2013;5(11):1698-1709.
57. Annoni A, Cantore A, Della Valle P, et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med. 2013;5(11):1684-1697.
58. Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010;116(26):5842-5848.
59. Doering CB, Gangadharan B, Dukart HZ, Spencer HT. Hematopoietic stem cells encoding porcine factor VIII induce procoagulant activity in hemophilia A mice with pre-existing factor VIII immunity. Mol Ther. 2007;15(6):1093-1099.
60. Kuether EL, Schroeder JA, Fahs SA, et al. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost. 2012;10(8): 1570-1580.